Chemo Spain – Leandro Sigman, General Manager
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Established over 35 years ago, Chemo operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, both for human and animal health.
While the main offices are located in Madrid, Lugano and Buenos Aires, Chemo is acting worldwide, creating a broad and balanced manufacturing and commercial network across major pharmaceutical markets in Europe, America, Asia and Africa, to address global opportunities and customers` needs.
Chemo`s activity is organized in three synergistic business areas: industrial, branded and biotech, with over 5,000 professionals in more than 40 countries, across four continents, ten state-of-the-art manufacturing facilities, nine specialized R&D centers, 12 commercial offices and 33 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
Chemo believes in innovation and sustainable development. The company’s commitment is to improve people`s health and quality of life, providing access to safe, quality and affordable medicines, and to continuously expand its efforts and R&D investment to develop new and better therapies.
Contact details:
Chemo Barcelona
Gran Vía Carlos III, 98 7th floor
08028 Barcelona , Spain.
Tel: + 34 93 330 62 12
Fax: + 34 93 330 27 62
BarcelonaChemo@chemogroup.com
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Alba Ancochea of FEDER, the association that groups together Spain’s 337 rare disease patient organizations, explains how it interacts with both government and industry to the benefit of rare disease…
Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the…
Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the challenges and opportunities of the Spanish pharma market, and…
María Ángeles Figuerola, director of SEVeM – the Spanish Medicines Verification System – introduces the mission and mandate of the institute, major challenges, and SEVeM’s role within Spain’s healthcare ecosystem. Please…
Enrique Sánchez de León, president of Fundamed, discusses the role of the voice of the patients, and how they work alongside the General Patient Alliance to strengthen this voice. Furthermore,…
Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines…
Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain,…
Lucas Sigman, director general of Chemo, a leader in the research, development and manufacture of finished dosage forms and the active pharmaceutical ingredient arm of Insud Pharma, highlights the 40…
Carlos Mateos, founder and CEO of Spanish digital healthcare PR specialist, COM Salud, discusses opportunities for the healthcare sector in eHealth and big data as well as the benefits that…
Dr. Ángel Navarro, president of Azierta discusses how the company’s strategy of linking science and business has created a consultancy space through which to offer a wide range of healthcare-related…
Eduardo Lopez-Puertas, managing director of IFEMA, Spain’s largest and most successful congress center, discusses the country’s competitive advantages compared to the rest of Europe, and the role the pharmaceutical sector…
Jose Manuel Rigueiro, general manager of the Spanish affiliate of Actelion, discusses the lack of trust between health authorities and the industry and the challenges of launching new orphan drugs…
See our Cookie Privacy Policy Here
